Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2016
At a glance
- Drugs KDT 501 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors KinDex Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 08 Jan 2016 Last checked against Clinicaltrials.gov record.
- 28 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to completed.